Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions
You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter
PHILADELPHIA — An investigational drug aimed at preventing strokes significantly reduced the risk of bleeding compared with a commonly used blood thinner for stroke prevention,
While high cholesterol, high blood pressure, diabetes and smoking are well known heart disease risks, not everyone who has a heart attack has them.
Three months after a large study of Novo Nordisk’s popular weight-loss and diabetes injection showed it cut major cardiovascular risks by 20%, further results from
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit
PHILADELPHIA — Dropping aspirin from the antithrombotic regimen after HeartMate 3 left ventricular assist device (LVAD) implantation appeared safer than the usual combination approach in
NASHVILLE, Tenn. — An investigational multitargeted drug produced objective responses in clear-cell renal cell carcinoma (ccRCC), irrespective of prior exposure to cabozantinib (Cabometyx), a small
The 24-hour news cycle is just as important to medicine as it is to politics, finance, or sports. At MedPage Today, new information is posted
PHILADELPHIA — The symptoms of stable angina can be eased by percutaneous coronary intervention (PCI) alone in the absence of antianginal medications, the randomized ORBITA-2